B of A Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice TargetHot
B of A Securities analyst Tazeen Ahmad maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $908 to $1030.
B of A Securities analyst Tazeen Ahmad maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $908 to $1030.